Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GRANULES

GRANULES (I)

HealthcarePharmaceuticals & Biotechnology₹19770 cr market cap
₹801.20 ▲ +0.46% today As of 19 Nov 2026
52-week low ₹532.8552-week high ₹909.30

-12.3% from the 52-week high · +49.7% above the low

Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 3,650 full-time employees. The firm operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The firm has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). The company has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. The firm sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. Its wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.

The short version. GRANULES (I) reported revenue of ₹1,560 crore for Sep 2026, up 20.3% from a year earlier. Net profit was ₹182 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 37.39% in Sep 2026, down 1.45 points over 8 quarters.

1 · The price

How has the stock traded?

GRANULES (I) trades 12.3% below its 52-week high and 49.7% above its 52-week low.

Change over period: —

1M-1.1%
3M-5.2%
6M+5.1%
1Y+42.0%

2 · The business

Is it growing?

Sales, year on year+20.3%

Sep 2026 revenue of ₹1,560 cr.

Profit, year on year+38.9%

Sep 2026 net profit of ₹182 cr.

Net margin11.7%

1.6 pts higher than a year earlier.

3-year growth4.8% profit

Revenue compounded at 6.0% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue15601477147113881297121011971138
Net profit182180202150131113152118
Net margin %11.712.213.710.810.19.312.710.3
EPS (₹)6.677.268.136.195.384.646.274.85

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue53664482450645123765323825992279
Net profit595502405517413549335236
Net margin %11.111.29.011.411.017.012.910.4
EPS (₹)24.0120.6816.7221.3416.6422.1813.199.3

3 · The quality

How well does it turn capital into profit?

Return on equity was 11.7% in Mar 2026; debt to equity is 0.26.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %11.713.512.618.2
Return on capital %16.018.019.024.0
EBITDA margin %22.222.019.120.5
Net margin %11.111.29.011.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR6.0%10.5%
Profit CAGR4.8%1.6%
Debt to equity0.26
Interest cover7.9x
Current ratio1.80
P/E ratio28.0

4 · The owners

Who holds it, and are they adding?

Promoter holding37.39%

Down 1.45 pts over 8 quarters.

Foreign institutions20.25%

Up 4.38 pts over 8 quarters.

Domestic institutions15.33%

Down 4.24 pts over 8 quarters.

Mutual fund schemes93

+12 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter38.8438.8438.8238.8238.8238.0238.0137.39-1.45
FII15.8715.1513.2414.0913.5515.3117.520.25+4.38
DII19.5722.4523.5317.9217.4817.0116.1115.33-4.24
Public25.7123.5724.4129.1730.1529.6628.3827.04+1.33

Mutual fund holdings · Oct 2026

93 schemes hold this stock

81 the month before.

  • Capitalmind Flexi Cap Fund3.57% of NAV
  • Old Bridge Focused Fund3.06% of NAV
  • Kotak Quant Fund3.05% of NAV
  • NJ Momentum Fund2.55% of NAV
  • UNION ACTIVE MOMENTUM FUND2.42% of NAV
  • ADITYA BIRLA SUN LIFE SMALL CAP FUND2.09% of NAV
  • ADITYA BIRLA SUN LIFE MULTI-CAP FUND1.91% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND1.87% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GRANULES (I) are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GRANULES (I)

What is the GRANULES (I) share price?

GRANULES (I) (GRANULES) last closed at ₹801.20, up 0.46% on the day. Its 52-week range is ₹532.85 to ₹909.30.

What is the market cap of GRANULES (I)?

GRANULES (I) has a market capitalisation of about ₹19,770 crore. Its price-to-earnings ratio is 28.0.

How are GRANULES (I)'s latest results?

GRANULES (I) reported revenue of ₹1,560 crore for Sep 2026, up 20.3% from a year earlier. Net profit was ₹182 crore (up 38.9% year on year). Return on equity was 11.7% in Mar 2026. Promoter holding was 37.39% in Sep 2026, down 1.45 points over 8 quarters.

Who owns GRANULES (I)?

As of Sep 2026, shareholding was: Promoter 37.39%, FII 20.25%, DII 15.33%, Public 27.04%.

How many mutual funds hold GRANULES (I)?

93 mutual fund schemes held GRANULES (I) in October 2026. That compares with 81 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 31 Jul 2025 · Final Dividend - Rs. 1.5
  • 30 Jul 2024 · Final Dividend - Rs. 1.5
  • 03 Aug 2023 · Final Dividend - Rs. 1.5
  • 19 Jul 2022 · Final Dividend - Rs. 0.75
  • 17 Feb 2022 · Interim Dividend - Rs. 0.25
  • 24 Nov 2021 · Interim Dividend - Rs. 0.25

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.